NCT04917874: A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa |
|
|
| Completed | 3 | 47 | US | Open Label Topical Beremagene Geperpavec (B-VEC) | Krystal Biotech, Inc. | Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa | 07/23 | 07/23 | | |
NCT06504160: Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2) |
|
|
| Not yet recruiting | 2 | 86 | US | ShA9 Topical Gel, Hydrocortisone Ointment, Clobetasol Ointment, Fluocinonide Ointment, Placebo (Vehicle) Topical Gel | National Institute of Allergy and Infectious Diseases (NIAID), Atopic Dermatitis Research Network (ADRN), Rho Federal Systems Division, Inc., PPD, Thermo Fisher Scientific Inc. | Atopic Dermatitis | 03/26 | 04/26 | | |
